IN VITRO-IN VIVO BIO-EQUIVALENCE CORRELATION STUDY OF METRONIDAZOLE, AND ITS BRANDS OF IMMEDIATE RELEASE TABLET UNDER BIO-WAIVER CONDITIONS

  • EM Ahmed College of Pharmacy, Department of Pharmaceutical Chemistry, Ribat National University, Khartoum, Sudan.
  • ME Ibrahim College of Pharmacy, Department of Pharmaceutical Chemistry, Ribat National University, Khartoum, Sudan.
  • FF Magbool https://orcid.org/0000-0003-0411-4120

Abstract

Objective: The aim of present study is to examine the in-vitro in-vivo correlation (IVIVC) of immediate release product. Metronidazole 500mg and its brands of immediate release dosage forms. Metronidazole is clearly classified into BCS class I, and could be evaluated under bio waiver conditions.
Methods: The in vitro parameters employed were hardness, weight uniformity, friability, disintegration time, absolute drug content, dissolution rate (in 0.1 N Hydrochloric acid, phosphate buffer and acetate buffer at 37ºC), and dissolution efficiencies were also analyzed. The in-vitro dissolution study was performed on the brands, according to FDA,USP dissolution profile in three different PH (1.2), (4.5), and (6.8) at37ºC, using the USP apparatus II, then f1, f2 were determined for the time intervals of 10, 15, 30, 45 and 60 minutes, and dissolution efficiencies were calculated. MINITAB 14 statistical program used for in vitro in vivo correlation, level A was done for reference product.
Results: A non linear relation was established which is typical for immediate release formulation, of class 1. There was significant relationship between in vitro and in vivo data of reference metronidazole product, Correlation and distribution of data with correlation coefficient (r=0.724, 0.837, 0.707), nonlinear relationship with p-value (>0.05) =(0.167, 0.098, 0.182), there is no out lines, no lake of fits at P-Values=0.0040, 006, 0.026.
Conclusion: Study concluded that there is no linear correlation between percent of drug released and percent of drug absorbed ,this may be due to uncontrollable gastric emptying rate for class one Metronidazole.


Peer Review History:


Received 2 January 2020;   Revised 1 February; Accepted 3 March, Available online 15 March 2020


UJPR follows the most transparent and toughest ‘Advanced OPEN peer review’ system. The identity of the authors and, reviewers will be known to each other. This transparent process will help to eradicate any possible malicious/purposeful interference by any person (publishing staff, reviewer, editor, author, etc) during peer review. As a result of this unique system, all reviewers will get their due recognition and respect, once their names are published in the papers. We expect that, by publishing peer review reports with published papers, will be helpful to many authors for drafting their article according to the specifications. Auhors will remove any error of their article and they will improve their article(s) according to the previous reports displayed with published article(s). The main purpose of it is ‘to improve the quality of a candidate manuscript’. Our reviewers check the ‘strength and weakness of a manuscript honestly’. There will increase in the perfection, and transparency.


Received file


pdf3.JPG


Average Peer review marks at initial stage: 4.5/10


Average Peer review marks at publication stage: 7.0/10


Reviewer(s) detail:


Name: Dr. Hayriye Eda Şatana Kara


Affiliation: Gazi University, Turkey


E-mail: eda@gazi.edu.tr


 


Name: Dr. Mohamed Ismail Nounou


Affiliation: Appalachian College of Pharmacy, Oakwood, Virginia, USA


E-mail: nounou@acp.edu


Comments of reviewer(s):


word_icon_3.jpg


Similar Articles:


IN VITRO-IN VIVO BIO-EQUIVALENCE CORRELATION STUDY OF ATENOLOL, AND ITS BRANDS OF IMMEDIATE RELEASE TABLET UNDER BIO-WAIVER CONDITIONS

Keywords: Bioavailability, bioequivalence, biopharmaceutical classification system, bio-waiver correlation
Statistics
54 Views | 58 Downloads
How to Cite
Ahmed, E., M. Ibrahim, and F. Magbool. “IN VITRO-IN VIVO BIO-EQUIVALENCE CORRELATION STUDY OF METRONIDAZOLE, AND ITS BRANDS OF IMMEDIATE RELEASE TABLET UNDER BIO-WAIVER CONDITIONS”. Universal Journal of Pharmaceutical Research, Vol. 5, no. 1, Mar. 2020, doi:https://doi.org/10.22270/ujpr.v5i1.360.
Section
Research Articles